Histone deacetylase inhibitors: from target to clinical trials

Bibliography

• MARKS PA, RIFKIND RA: Erythroleukemic differentiation. Ann. Rev Biochem. (1978) 47:419–478.
   PubMed Web of Science ®Google Scholar
• ••First comprehensive review of inducers oftransformed cell differentiation.
   Google Scholar
• MARKS PA, RIFKIND RA, RICHON VM et al.: Histone deacetylases and cancer: causes and therapies. Nat. Rev Cancer (2001) 1:194–202.
   PubMed Web of Science ®Google Scholar
• JENLTWEIN T, ALLIS CD: Translating the histone code. Science (2001) 293:1074–1080.
   PubMed Web of Science ®Google Scholar
• ••Exposition of the histone code' hypothesisrelating to post-translational modification of histones.
   Google Scholar
• CHEUNG P, ALLIS CD, SASSONE-CORSI P: Signaling to chromatin through histone modifications. Cell (2000) 103:263–271.
   PubMed Web of Science ®Google Scholar
• WOLFFE AP, PRUSS D: Deviant nucleosomes: the functional specialization of chromatin. Trends Genet. (1996) 12:58–62.
   PubMed Web of Science ®Google Scholar
• STRAHL BD, ALLIS CD: The language of covalent histone modifications. Nature (2000) 403:41–45.
   PubMed Web of Science ®Google Scholar
• ••Role of post-translational histonemodification in regulating gene expression.
   Google Scholar
• TURNER BM: Histone acetylation and an epigenetic code. Bioessays (2000) 22: 836–845.
   PubMed Web of Science ®Google Scholar
• ••Reviews the selective aspects of histoneacetylation.
   Google Scholar
• REA SF, EISENHABER F, O'CARROLL BD et al.: Regulation of chromatin structure by site-specific histone H3 methyltransferase. Nature (2000) 406:593–599.
   Google Scholar
• KHOCHBIN S, VERDEL A, LEMERCIER C, SEIGNEURIN-BERNY D: Functional significance of histone deacetylase diversity. Carr: Opin. Genet. Dev. (2001) 11:162–166.
   PubMed Web of Science ®Google Scholar
• NG HH, BIRD A: Histone deacetylases: silencers for hire. Trends Biochem. Sci. (2000) 25:121–126.
   PubMed Web of Science ®Google Scholar
• URNOV FD, WOLFFE A: Chromatin organization and human disease. Emerg. Ther. Targets (2000) 4: 665–685.
   Google Scholar
• ••Reviews alterations in HAT and HDACfunction in disease, particularly cancers.
   Google Scholar
• MAHIKNECHT U, HOELZER D: Histone acetylation modifiers in the pathogenesis of malignant disease. Ma Med. (2000) 6:623–644.
   Google Scholar
• TIMMERMANN S, LEHRMANN H, POLESSKAYA A, HAREL-BELLAN A: Histone acetylation and disease. Cell. Ma Life Sci. (2001) 58:728–736.
   PubMed Web of Science ®Google Scholar
• CRESS WD, SETO E: Histone deacetylases, transcriptional control and cancer.j Cell. Physiol (2000) 184:1–16.
   PubMed Web of Science ®Google Scholar
• CAMERON EE, BACHMAN KE, MYOHANEN S et al.: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. (1999) 21:103–107.
   PubMed Web of Science ®Google Scholar
• WANG C, FU M, MANI S et al: Histoneacetylation and the cell-cycle in cancer. Front. Biosci. (2001) 6:610–629.
   PubMed Web of Science ®Google Scholar
• VIGUSHIN DM, COOMBES RC: Histone deacetylase inhibitors in cancer treatment. Anti-Cancer Drugs (2002) 13:1–13.
   PubMed Web of Science ®Google Scholar
• JONES PA, BAYLIN SB: The fundamental role of epigenetic events in cancer. Nature Rev. Genet. (2002) 3:415–428.
   PubMed Web of Science ®Google Scholar
• ••Good review of epigenetic modification ofgene expression in cancers.
   Google Scholar
• SPECK NA, GILLILAND DG: Core-binding factors in haematopoiesis and leukaemia. Nat. Rev Cancer (2002) 2:502–513.
   PubMed Web of Science ®Google Scholar
• MARKS PA, RICHON VM, RIFKIND RA: Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells." Natl. Cancer Inst. (2000) 92:1210–1216.
   PubMed Web of Science ®Google Scholar
• VAN LINT C, EMILIANI S, VERDIN E: The expression of a small fraction of cellular gene is changed in response to histone hyperacetylation. Gene Expc (1996) 5:245–254.
   PubMed Web of Science ®Google Scholar
• ••Demonstrated that HDAC inhibitor, TSA,was selective in genes whose expression was altered.
   Google Scholar
• BUTLER LM, ZHOU X., XU W-S et al.:The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc. Natl. Acad. Sci. USA (2002) 99:11700–11705.
   Google Scholar
• SUZUKI H, GABRIELSON E, CHEN W et al.: A genomic screen for genes upregulated by demethylation and histone deacetylase inhibitors in human colorectal cancer. Nat. Genet. (2002) 31:141–149.
   PubMed Web of Science ®Google Scholar
• ROGIONE FD, CRINITE V, DELLA-PIETRA V et al.: Genes modulated by histone acetylation as new effectors of butyrate activity. FEBS (2001) 499:199–204.
   PubMed Web of Science ®Google Scholar
• LUGER K, MADER AW, RICHMOND RK et al.: Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature (1997) 389:231–233.
   Google Scholar
• GREGORY PD, WAGNER K, HORZ W: Histone acetylation and chromatin remodeling. Exp. Cell Res. (2001) 265:195–202.
   PubMed Web of Science ®Google Scholar
• DAVIE JR: Covalent modifications of histones: expression from chromatin templates. Curr. Opin. Genet. Dev. (1998) 8:173–174.
   PubMed Web of Science ®Google Scholar
• KOUZARIDES T: Acetylation: a regulatory modification to rival phosphorylation? EMBO J. (2000) 19:1176–1179.
   Google Scholar
• TURNER BM: Histone acetylation and an epigenic code. BioEssays (2000) 22:836–845.
   PubMed Web of Science ®Google Scholar
• BIRD A: Methylation talk between histones and DNA. Science (2001) 294:2113–2115.
   PubMed Web of Science ®Google Scholar
• BANNISTER AJ, ZEGERMAN P, PARTRIDGE JF et al: Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature (2001) 410:120–124.
   PubMed Web of Science ®Google Scholar
• NAKAYAMA J-I, RICE JC, STRAHL BD et al.: Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science (2001) 292:110–113.
   PubMed Web of Science ®Google Scholar
• STERNER DE, BERGER SL: Acetylationof histones and transcription-related factors. Microbiol Ma Biol. Rev (2000) 64:435–459.
   PubMed Web of Science ®Google Scholar
• YANG X-J, OGRYZKO VV, NISHIKAWA J-I: A P300/CBP-associated factor that competes with the adenoviral oncoprotein ElA. Nature (1996) 382:319–324.
   PubMed Web of Science ®Google Scholar
• ROTH SY, DENU JM, ALLIS CD: Histone acetyltransferases. Ann. Rev. Biochem. (2001) 70:81–120.
   PubMed Web of Science ®Google Scholar
• ••Review of the structure, diversity andfunction of HATs.
   Google Scholar
• DECKERT J, STRUHL K: Histone acetylation at promoters is differentially affected by specific activators and repressors. MolCell Biol. (2001) 8:2726–2735.
   Google Scholar
• GREGORY PD: Histone acetylation and chromatin remodeling. Exp. Cell Res. (2001) 265:195–202.
   PubMed Web of Science ®Google Scholar
• GRAY GG, EKSTROM TJ: The human histone deacetylase family. Exp. Cell Res. (2001) 262:75–83.
   PubMed Web of Science ®Google Scholar
• ZHOU X, MARKS PA, RIFKIND RA etal.: Cloning and characterization of a histone deacetylase, HDAC9. Proc. Natl. Acad. Sci. USA (2001) 98:10572–10577.
   Google Scholar
• GROZINGER CM, HASSIG CA, SCHREIBER SL: Three proteins define a class of human histone deacetylases related to yeast Hdalp. Proc. Natl. Acad. Sci. USA (1999) 96:4868–4873.
   PubMed Web of Science ®Google Scholar
• GAOL, CUETO MA, ASSELBERGS F, ATAOJA P: Cloning and functional characterization of HDAC II, a novel member of the human histone deacetylase family. J. Biol Chem. (2002) 277:25748–25755.
   PubMed Web of Science ®Google Scholar
• KAO H-Y, LEE C-H, KOMAROV A et al.:Isolation and characterization of mammalian HDAC10, a novel histone deacetylase. J. Biol. Chem. (2002) 277:187–193.
   PubMed Web of Science ®Google Scholar
• FISCHER DD, CAI R, BHATIA U etal.: Isolation and characterization of a novel class II histone deacetylase, HDAC10.1. Biol. Chem. (2002) 277:6656–6666.
   Google Scholar
• GUARDIOLA AR, YAO TP: Molecular cloning and characterization of a novel histone deacetylase HDAC10../. Biol. Chem. (2002) 277:3350–3356.
   PubMed Web of Science ®Google Scholar
• LANDRY J, SUTTON A, STEFAN T, TAFROV RC, STEBINS J: The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc. Natl. Acad. Sci. USA (2000) 97:5807–5811.
   PubMed Web of Science ®Google Scholar
• FRYE RA: Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem. Biophys. Res. Commun. (2000) 273:793–798.
   PubMed Web of Science ®Google Scholar
• ALLAND L, MUHLE R, HOU JR et al: Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature (1997) 387:49–55.
   PubMed Web of Science ®Google Scholar
• HEINZEL T, LAVINSKY RM, MULLEN TM et al.: A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature (1997) 387:43–48.
   PubMed Web of Science ®Google Scholar
• JOHNSON CA, WHITE DA, LAVENDER JS et al.: Human class I histone deacetylase complexes show enhanced catalytic activity in the presence of ATP and co-immunoprecipate with the ATP-dependent chaperone protein HSP70. Biol. Chem. (2002) 277:9590–9597.
   Web of Science ®Google Scholar
• LU J, McKINSEY TA, ZHANG C-L et al:Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases. Ma Cell (2000) 6:233–244.
   PubMed Web of Science ®Google Scholar
• BERNSTEIN BE, TONG JK, SCHREIBER SL: Genome wide studies of histone deacetylase in yeast. Proc. Natl. Acad. Sci. USA (2000) 97:13708–13713.
   PubMed Web of Science ®Google Scholar
• ••Evidence for the potential differentialfunctions of HDACs.
   Google Scholar
• CHAN HM, KASTIC-DEMONACOS M, SMITH L et al.: Acetylation control of the retinoblastoma tumor-suppressor protein. MM. Cell Biol. (2001) 3:667–674.
   Google Scholar
• ••Evidence for the role of HDACs inregulation of cell cycle progression.
   Google Scholar
• NAGY L, KAO HY, CHATERAVATI D et al.: Nuclear receptor repression mediated by a complex containing SMRT, mSin3A and histone deacetylase. Cell (1997) 89:373–380.
   PubMed Web of Science ®Google Scholar
• ITO K, BARNES PJ, ADCOCK IM: Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin- 1-'3 induced histone H4 acetylation on lysines 8 and 12. Ma Cell Biol. (2000) 20:6891–6903.
   Web of Science ®Google Scholar
• CAI RL, YAN-NEALE Y, CUETO MA, XU H, COHEN D: HDAC1 a histone deacetylase, forms a complex with Husl and Rad9, two G2/M checkpoint Rad proteins. J. Biol. Chem. (2000) 275:27909–27916.
   PubMed Web of Science ®Google Scholar
• ROBERTSON KD, AIT-SI-ALI S, YOKOCHI T, WADE PA, JONES PL, WOLFFE AP: DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat. Genet. (2000) 25:338–342.
   PubMed Web of Science ®Google Scholar
• SMIRNOV DA, HOU S, RICCIARDI RP: Association of histone deacetylase with COUP-TF in tumorigenic Ad12-transformed cells and its potential role in shut-off of MHC class 1 transcription. Virology (2000) 268:319–328.
   PubMed Web of Science ®Google Scholar
• GILES RH, PETERS DJ, BREUNING MH: Conjunction dysfunction: CBP/p300 in human disease. Trends Genet. (1998) 14:178–183.
   PubMed Web of Science ®Google Scholar
• GAYTHER SA, BATLEY SJ, LINGER L, BANNISTER A et al.: Mutations truncating the EP300 acetylase in human cancers. Nature Genet. (2000) 24:300–303.
   PubMed Web of Science ®Google Scholar
• MURATA T, KUROKAWA R, KRONES A et al Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome. Hum. MM. Genet. (2001) 10:1071–1076.
   PubMed Web of Science ®Google Scholar
• ••Defect in HAT activity shown associatedwith increased risk for cancers.
   Google Scholar
• MAGNAGHI-JAULIN L, GROISMAN R, NAGUIBNEVA I et al: Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature (London) (1998) 391:601–605.
   PubMed Web of Science ®Google Scholar
• ••Cell cycle regulatory protein and HDACsinteraction.
   Google Scholar
• MURPHY M, AHN J, WALKER KK et al.:Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. (1999) 13:2490–2501.
   PubMed Web of Science ®Google Scholar
• YARDEN RI, BRODY LC: BRCA1 interacts with components of the histone deacetylase complex. Proc. Nati Acad. Sci. USA (1999) 96:4983–4988.
   PubMed Web of Science ®Google Scholar
• FENICK R, HIEBERT SW: Role of histone deacetylase in acute leukemia. J. Biochem. (1998) 31:194–202.
   Google Scholar
• HE L-Z, TOLENTINO T, GRAYSON P et al.: Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyleocytic leukemia. Clin. Invest. (2001) 108:1321–1330.
   Google Scholar
• •Predinical study of HDAC inhibitors in therapy of leukaemia.
   Google Scholar
• WANG J, HOSHINO T, REDNER RL et al.: ETO, fusion partner in t(8:21) acute myeloid leukemia, represses transcription by interaction with the human N-Co-R/ mSin3/HDAC1 complex. Proc. Nati Acad. Sci. USA (1998) 95:10860–10865.
   PubMed Web of Science ®Google Scholar
• KRAMER OH, GOTTLICHER M, HEINZEL T: Histone deacetylase as a therapeutic target. Trends Endocrinol Metab. (2001) 12:294–300.
   PubMed Web of Science ®Google Scholar
• MARKS PA, RICHON VM, BRESLOW R et al.: Histone deacetylase inhibitors as new cancer drugs. Carr: Opin. Oncol (2001) 13:477–485.
   PubMed Web of Science ®Google Scholar
• GLASER KB, LI J, AAKRE ME et al.: Transforming growth factor 13 mimetics: discovery of 7+1-(4-cyanophenyl)phenoxyl-heptanohydroxamic acid, a biaryl hydroxamate inhibitor of histone deacetylase. MM. Cancer The]: (2002) 1:759–768.
   Google Scholar
• UESATO S, KITAGAWA M, NAGAOKA Y et al: Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a terminal bicyclic aryl group. Bioorg. Med. Chem. Lett. (2002) 12:1347–1349.
   PubMed Web of Science ®Google Scholar
• LAVOIE R, BOUCHAIN G, FRECHETTE S: Design and synthesis of a novel class of histone deacetylase inhibitors.
   Google Scholar
• •• Bioorg. Med. Chem. Lett. (2001) 11:2847–2850.
   Google Scholar
• NEWMARK HL, LUPTON JR, YOUNG CW: Butyrate as a differentiating agent: pharmacokinetics analogues and current status. Cancer Lett. (1994) 78:1–5.
   PubMed Web of Science ®Google Scholar
• CARDUCCI MA, BOWLING MK, EISENBERGER M et al.: Phenylbutyrate (PB) for refractory solid tumors: Phase I clinical and pharmacologic evaluation of intravenous and oral PB. Anticancer Res. (1997) 17:3972–3973.
   Google Scholar
• THIBAUDT A, COOPER MR, FIGG WD et al.: A Phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res. (1994) 54:1690.
   PubMed Web of Science ®Google Scholar
• CONLEY BA, EGORIN MJ, TAIT H et al: Phase I study of orally administered butyrate prodrug tubutepin, in patients with solid tumors. Clin. Cancer Res. (1998) 4:629–634.
   PubMed Web of Science ®Google Scholar
• GORE SD, CARDUCCI MA: Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert Opin. Investig. Drugs (2000) 9:2923–2934.
   PubMed Web of Science ®Google Scholar
• GILBERT J, BAKER SD, BOWLING MK et al.: A Phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Gin. Cancer Res. (2001) 7:2292–2300.
   Web of Science ®Google Scholar
• WARRELL RP, HE LZ, RICHON VM et al.: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst. (1998) 90:1621–1625.
   PubMed Web of Science ®Google Scholar
• NOVICH S: Initial clinical evaluation of transcription therapy for cancer: all-trans retinoic acid plus phenylbutyrate. Blood (1999) 94:61A. ao.PHIEL CJ, ZHANG F, HUANG EY et al.: Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. (2001) 276:36734–36741.
   Google Scholar
• GOTTLICHER M, MINUCCI S, ZHU P et al.: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO (2001) 20:6969–6978.
   PubMed Web of Science ®Google Scholar
• YOSHIDA M, KIJIMA M, AKITA M, BEPPU T: Potent and specific inhibition of mammalian histone deacetylase both in vivo and M vitro by trichostatin A. j Biol. Chem. (1990) 265:17174–17179.
   PubMed Web of Science ®Google Scholar
• •Identification of HDACs as a target for TSA.
   Google Scholar
• RICHON VM, EMILIANI S, VERDIN E et al.: A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. USA (1998) 95:3003–3007.
   PubMed Web of Science ®Google Scholar
• ••Discovery of a series of hydroxamic acid-based hybrid polar compounds that are potent inhibitors of HDACs.
   Google Scholar
• KIM YB, LEE KH, SUGITA K, YOSHIDA M, HORINOUCHI S: Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene (1999) 18:2461–2470.
   PubMed Web of Science ®Google Scholar
• BUTLER LM, AGUS D, SCHER HI et aL: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells M vitro and in vivo. Cancer Res. (2000) 60:5165–5170.
   PubMed Web of Science ®Google Scholar
• •Demonstration that the HDAC inhibitor, SAHA, can suppress prostate cancer growth in mice at doses that have no apparent toxicity.
   Google Scholar
• BUTLER LM, WEBB Y, AGUS DB et al.: Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Gin. Cancer Res. (2001) 7:962–970.
   Web of Science ®Google Scholar
• HUANG L, PARDEE AB: Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol. Med. (2000) 6:849–866.
   PubMed Web of Science ®Google Scholar
• RICHON VM, WEBB Y, MERGER R, SHEPPARD T et al: Second generation hybrid polar compounds are portent inducers of transformed cell differentiation. Proc. Nati Acad. Sci. USA (1996) 93:5705–5708.
   PubMed Web of Science ®Google Scholar
• SU GH, SOHN TA, RYU BA: A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res. (2000) 60:3137–3142.
   PubMed Web of Science ®Google Scholar
• LAVOIE R, BOUCHAIN G, FRECHETTE S et al.: Design and synthesis of a novel class of histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. (2001) 11:2847–2850.
   PubMed Web of Science ®Google Scholar
• QUI L, KELSO MJ, HANSEN C, WEST ML, FAIRLIE DP, PARSONS PG: Anti-tumor activity M vitro and in vivo of selective differentiating agents containing hydroxamate. Br.j Cancer (1999) 80:1252–1258.
   PubMed Web of Science ®Google Scholar
• PARSONS PG, HANSEN C, FAIRLIE DP et al.: Tumor selectivity and transcriptional activation by azelaic bishydroxamic acid in human melanocytic cells. Biochem. Pharmacol. (1997) 53:1719–1724.
   PubMed Web of Science ®Google Scholar
• KIJIMA M, YOSHIDA M, SUGITA K, HORINOUCHI S, BEPPU T: Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. Biol. Chem. (1993) 268:22429–22435.
   Web of Science ®Google Scholar
• NAKAJIMA H, KIM YB, TERANO H, YOSHIDA M, HORINOUCHI S: FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. (1998) 241:126–133.
   PubMed Web of Science ®Google Scholar
• MURRAY PJ, KRANZ M, LADLOW M et al.: The synthesis of cyclic tetrapeptoid analogues of the antiprotozoal natural product apicidin. Bioorg. Med. Chem. Lett. (2001) 11:773–776.
   PubMed Web of Science ®Google Scholar
• MEINKE PT, COLLETTI SL, DOSS G et al.: Synthesis of apicidin-derived quinolone derivatives: parasite-selective histone deacetylase inhibitors and antiproliferative agents. J. Med. Chem. (2000) 43:4919–4922.
   PubMed Web of Science ®Google Scholar
• KOSUGI H, ITO M, YAMAMOTO Y et al.: In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyeocytic leukemia in NOD/Shi-scid/ scid mice. Jpn. J. Cancer Res. (2001) 92:529–536.
   PubMedGoogle Scholar
• SUZUKI T, ANDO T, TSUCHIYA K, et al.: Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J. Med. Chem. (1999) 42:3001–3003.
   Google Scholar
• SAITO A, YAMASHITA T, MARIKO Y et al.: A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci USA (1999) 96:4592–4597.
   PubMed Web of Science ®Google Scholar
• KWON HJ, OWA T, HASSIG CA, SHIMADA J, SCHREIBER SL: Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc. Natl. Acad. Sci. USA (1998) 95:3356–3361.
   PubMed Web of Science ®Google Scholar
• FINNIN MS, DONIGIAN JR, COHEN A et al: Structures of a histone deacetylase homologue bound to TSA and SAHA inhibitors. Nature (1999) 401:188–193.
   PubMed Web of Science ®Google Scholar
• ••Crystal structure of the catalytic site ofHDAC and the binding of inhibitors, TSA and SAHA, in the site.
   Google Scholar
• RICHON VM, SANDHOFF TW, RIFKIND RA et al.: Histone deacetylase inhibitors selectively induce p21"41 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA (2000) 97:10014–10019.
   PubMed Web of Science ®Google Scholar
• SAMBUCETTI LC, FISCHER DD, ZABLUDOFF S et al.: Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. Biol. Chem (1999) 274:34940–34947.
   Web of Science ®Google Scholar
• YOSHIDA M, HORINOUCHI S, BEPPU T: Trichostatin A and novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays (1995) 17:423–430.
   PubMed Web of Science ®Google Scholar
• XIAO H, HASEGAWA T, ISOBE K: Both Spl and Sp3 are responsible for p2 lwafl promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells. J. Cell Biochem. (1999) 73:291–302.
   PubMed Web of Science ®Google Scholar
• JOHNSTONE RW: Histone deacetylase inhibitors: Novel drugs for the treatment of cancer. Nature Rev Drug Discov. (2002) 1:287–299.
   PubMed Web of Science ®Google Scholar
• VRANA JA, DECKER RH, JOHNSON CR et al.: Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bc1-2/Bc1-XL, c-Jun, and p211 CIP1, but independent of p53. Oncogene (1999) 18:7016–7025.
   PubMed Web of Science ®Google Scholar
• MACLEOD KF, SHERRY N, HANNON G et al.: p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. (1995) 9:935–944.
   PubMed Web of Science ®Google Scholar
• TAKAKURA M, KYO S, SOWA Y et al: Telomerase activation by histone deacetylase inhibitor in normal cells. Nucleic Acids Res. (2001) 29:3006-3011. llo. BRINKMANN H, DAHLER AL, POPA C et al.: Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts. J. Biol. Chem. (2001) 276:22491–22499.
   Google Scholar
• KIM MS, KWON HJ, LEE YM et al.: Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. (2001) 7:437–443.
   PubMed Web of Science ®Google Scholar
• KWON HJ, KIM MS, KIM MJ, NAKAJIMA H, KIM KW: Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int. Cancer (2002) 97(3)290–296.
   Google Scholar
• DEROANNE CE BONJEAN K, SERVOTTE S et al.: Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene (2002) 21:427–436.
   PubMed Web of Science ®Google Scholar
• THIBAULT A, SAMID D, COOPER MR et al.: Phase I study of Phenylacetate administered twice daily to patients with cancer. Cancer (1995) 75:2932–2938.
   PubMed Web of Science ®Google Scholar
• CHANG S, KUHN J, ROBINS I et al.: Phase II study of phenylacetate in patients with recurrent malignant gliomas: a north American brain tumor consortium report. Clin. Onc. (1999) 17:984–990.
   Web of Science ®Google Scholar
• CARDUCCI MA, NELSON JB, CHAN-TACK KM et al.: Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin. Cancer Res. (1996) 2:379–387.
   PubMed Web of Science ®Google Scholar
• GORE SD, MILLER CB, WENG LJ et al: Clinical development of sodium phenylbutyrate as putative differentiating agent in myeloid malignancies. Anticancer Res. (1997) 17:3938.
   Google Scholar
• ZHOU D, KIM S, DING W, SCHULTZ C, WARRELL R, GALLAGHER R: Frequent mutations in the ligand-binding domain of PML-RARa after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and deacetylase inhibitors in vitro and in vivo. Blood (2002) 99:1356–1363.
   PubMed Web of Science ®Google Scholar
• GILBERT J, BAKERS, DONEHOWER R et al: Methyltransferase (MT) activity and gene expression in tumor biopsies from patients enrolled in a Phase I study of the MT inhibitor, 5-Azacytidine and histone deacetylase inhibitor, phenylbutyrate in refractory solid tumors. Proc. Am. Soc. clip.. Onc. (2001):87a (Abstract).
   Google Scholar
• KEER H, REID T, SREEDHARAN S: Pivanex activity in refractory non-small cell lung cancer, a Phase II study. Proc. Am. Soc. Clin. Onc. (2001):314a (Abstract).
   Google Scholar
• GOTTLICHER M, MINUCCI S, ZHU P et al.: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO (2001) 20:6969–6978.
   PubMed Web of Science ®Google Scholar
• KELLY WK, RICHON VM, TROSO-SAND OVALT et al.: Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor: biologic activity without toxicity. Proc. Am. Soc. Clin. Onc. (2001):87a (Abstract).
   Google Scholar
• KELLY WK, O'CONNOR 0, RICHON VM ET AL: A Phase I clinical trial of an oral formulation of the histone deacetylase inhibitor of suberoylanilide hydroxamic acid (SAHA). 14th EORTC-NCI-AACR, Frankfurt (2002):286 (Abstract).
   Google Scholar
• O'CONNOR OA, KELLY WK, WANG E et al.: Clinical development of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in agressive non-Hodgkin's lymphoma and Hodgkin's disease. Proceedings of the 43rd Annual American Society of Hematology (2001):2562 (Abstract).
   Google Scholar
• NAKAJIMA H, KIM YB, TERANO H, YOSHIDA M, HORINOUCHI S: FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. (1998) 241:126–128.
   PubMed Web of Science ®Google Scholar
• SANDOR V, BAKKE S, ROBEY R et al,: Phase I trial of a novel antitumor depsipeptide (FR 901228) in patients with refractory neoplasms. Clin. Cancer Res. (2001) 8:718–728.
   Google Scholar
• PIEKARZ R, ROBEY R, BAKKE S, SAND OR V, WILSON W, BATES S: Histone deacetylase inhibitor for the treatment of peripheral or cutaneous T-cell lymphoma. Proc. Am. Soc. Clin. Onc. (2001):23213 (Abstract).
   Google Scholar
• PIEKARZ RL, ROBEY R, SANDOR V et al.: Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood(2001) 98:2865–2868.
   PubMed Web of Science ®Google Scholar
• PRAKASH S, FOSTER B, MEYER M et al.: Chronic administration of CI-994: a Phase I study. Invest. New Drugs (2001) 19:1–11.
   PubMed Web of Science ®Google Scholar
• WOZNIAK A, O'SHAUGHNESSY J, FIORICA J, GROVE W: Phase II trial of CI-994 in patients with advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Onc. (1999):487a (Abstract).
   Google Scholar
• O'SHAUGHNESSY J, FLAHERTY L, FIORICA J, GROVE W: Phase II trial of CI-994 in patients with metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Onc. (1999):349a (Abstract).
   Google Scholar
• KIMMEL KA, KINDLER HL, JANISCH S, OLSON S, GROVE W: Phase I dose-finding study of CI-994 in combination with capecitabine in patients with advanced solid tumors. Proc. Am. Soc. Clin. Onc. (2001):87a (Abstract).
   Google Scholar
• OLIVARES J, WILLIAMS A, OLSON S, PAUER LR, GROVE W: Phase I pharmacokinetic study of CI-994 in combination with carboplatin and paclitaxel in patients with advanced solid tumors. Proc. Am. Soc. Clin. Onc. (2001) :87a (Abstract).
   Google Scholar
• ARDIZZONI A, LOPREVITE M: Histone deacetylation inhibitors. New Drugs in Lung Cancer S52–S54.
   Google Scholar